[1]
|
庞兴学, 王显. 血栓形成的过程与机制研究进展[J]. 医学综述, 2011, 17(11): 1613-1616.
|
[2]
|
ISTH Steering Committee for World Thrombosis Day (2014) Thrombosis: A Major Contributor to the Global Disease Burden. Journal of Thrombosis and Haemostasis: JTH, 12, 1580-1590. https://doi.org/10.1111/jth.12698
|
[3]
|
Wolberg, A.S., Rosendaal, F.R., Weitz, J.I., et al. (2015) Venous Thrombosis. Nature Reviews Disease Primers, 1, Article No. 15006. https://doi.org/10.1038/nrdp.2015.6
|
[4]
|
Lippi, G., Franchini, M. and Targher, G. (2011) Arterial Thrombus For-mation in Cardiovascular Disease. Nature Reviews Cardiology, 8, 502-512. https://doi.org/10.1038/nrcardio.2011.91
|
[5]
|
Mackman, N. (2012) New Insights into the Mechanisms of Venous Thrombosis. The Journal of Clinical Investigation, 122, 2331-2336. https://doi.org/10.1172/JCI60229
|
[6]
|
Asada, Y., Yamashita, A., Sato, Y. and Hatakeyama, K. (2020) Pathophysiology of Atherothrombosis: Mechanisms of Throm-bus Formation on Disrupted Atherosclerotic Plaques. Pathology International, 70, 309-322.
https://doi.org/10.1111/pin.12921
|
[7]
|
Li, X., Guo, T., Feng, Q., et al. (2022) Progress of Thrombus Formation and Research on the Structure-Activity Relationship for Antithrombotic Drugs. European Journal of Medicinal Chemis-try, 228, Article ID: 114035.
https://doi.org/10.1016/j.ejmech.2021.114035
|
[8]
|
Mackman, N. (2008) Triggers, Targets and Treatments for Thrombosis. Nature, 451, 914-918.
https://doi.org/10.1038/nature06797
|
[9]
|
Duffett, L. (2022) Deep Venous Thrombosis. Annals of Internal Medicine, 175, ITC129-ITC144.
https://doi.org/10.7326/AITC202209200
|
[10]
|
Munnix, I.C.A., Cosemans, J.M.E.M., Auger, J.M. and Heemskerk, J.W.M. (2009) Platelet Response Heterogeneity in Thrombus Formation. Thrombosis and Haemostasis, 102, 1149-1156. https://doi.org/10.1160/TH09-05-0289
|
[11]
|
史旭波, 胡大一. 血栓形成与凝血机制及调节[J]. 临床荟萃, 2007, 22(14): 989-991.
|
[12]
|
Bryckaert, M., Rosa, J.P., Denis, C.V. and Lenting, P.J. (2015) Of von Willebrand Factor and Platelets. Cellular and Molecular Life Sciences: CMLS, 72, 307-326. https://doi.org/10.1007/s00018-014-1743-8
|
[13]
|
Prasannan, N. and Scully, M. (2021) Novel Antiplatelet Strategies Targeting VWF and GPIb. Platelets, 32, 42-46.
https://doi.org/10.1080/09537104.2020.1786038
|
[14]
|
Fujimura, Y., Titani, K., Holland, L.Z., et al. (1986) von Willebrand Factor: A Reduced and Alkylated 52/48-kDa Fragment Beginning at Amino Acid Residue 449 Contains the Domain Interacting with Platelet Glycoprotein Ib. The Journal of Biological Chemistry, 261, 381-385. https://doi.org/10.1016/S0021-9258(17)42483-5
|
[15]
|
Robert, A., Shen, Y., Elizabeth, G., et al. (1999) The Glyco-protein Ib-IX-V Complex in Platelet Adhesion and Signaling. Thrombosis and Haemostasis, 81, 357-364. https://doi.org/10.1055/s-0037-1615854
|
[16]
|
Versteeg, H.H., Heemskerk, J.W., Levi, M. and Reitsma, P.H. (2013) New Fundamentals in Hemostasis. Physiological Reviews, 93, 327-358. https://doi.org/10.1152/physrev.00016.2011
|
[17]
|
Jackson, S.P. (2011) Arterial Thrombosis—Insidious, Unpre-dictable and Deadly. Nature Medicine, 17, 1423-1436.
https://doi.org/10.1038/nm.2515
|
[18]
|
Zaffran, Y., Meyer, S.C., Negrescu, E., Reddy, K.B. and Fox, J.E.B. (2000) Signaling across the Platelet Adhesion Receptor Glycoprotein Ib-IX Induces αIIbβ3 Activation both in Platelets and a Transfected Chinese Hamster Ovary Cell System. The Journal of Biological Chemistry, 275, 16779-16787. https://doi.org/10.1074/jbc.275.22.16779
|
[19]
|
Jackson, S.P., Nesbitt, W.S. and Westein, E. (2009) Dynamics of Platelet Thrombus Formation. Journal of Thrombosis and Haemostasis: JTH, 7, 17-20. https://doi.org/10.1111/j.1538-7836.2009.03401.x
|
[20]
|
De Meyer, S.F., De Maeyer, B., Deckmyn, H. and Vanhoorelbeke, K. (2009) Von Willebrand Factor: Drug and Drug Target. Cardiovascular and Hematological Disorders Drug Targets, 9, 9-20.
https://doi.org/10.2174/187152909787581327
|
[21]
|
O’Connor, S.D., Taylor, A.J., Williams, E.C. and Winter, T.C. (2009) Coagulation Concepts Update. AJR American Journal of Roentgenology, 193, 1656-1664. https://doi.org/10.2214/AJR.08.2191
|
[22]
|
van der Meijden, P.E., Munnix, I.C., Auger, J.M., et al. (2009) Dual Role of Collagen in Factor XII-Dependent Thrombus Formation. Blood, 114, 881-890. https://doi.org/10.1182/blood-2008-07-171066
|
[23]
|
Mackman, N., Tilley, R.E. and Key, N.S. (2007) Role of the Extrinsic Pathway of Blood Coagulation in Hemostasis and Thrombosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 27, 1687-1693.
https://doi.org/10.1161/ATVBAHA.107.141911
|
[24]
|
Reininger, A.J., Bernlochner, I., Penz, S.M., et al. (2010) A 2-Step Mechanism of Arterial Thrombus Formation Induced by Human Atheroscleroticplaques. Journal of the American College of Cardiology, 55, 1147-1158.
https://doi.org/10.1016/j.jacc.2009.11.051
|
[25]
|
Mattheij, N.J., Swieringa, F., Mastenbroek, T.G., et al. (2016) Coated Platelets Function in Platelet-Dependent Fibrin Formation via Integrin αIIbβ3 and Transglutaminase Factor XIII. Haematologica, 101, 427-436.
https://doi.org/10.3324/haematol.2015.131441
|
[26]
|
Brinjikji, W., Madalina Mereuta, O., Dai, D., et al. (2021) Mechanisms of Fibrinolysis Resistance and Potential Targets for Thrombolysis in Acute Ischaemic Stroke: Lessons from Retrieved Stroke Emboli. Stroke and Vascular Neurology, 6, 658-667. https://doi.org/10.1136/svn-2021-001032
|
[27]
|
Cushman, M. (2007) Epidemiology and Risk Factors for Venous Thrombosis. Seminars in Hematology, 4, 62-69.
https://doi.org/10.1053/j.seminhematol.2007.02.004
|
[28]
|
Noble, S. and Pasi, J. (2010) Epidemiology and Patho-physiology of Cancer-Associated Thrombosis. British Journal of Cancer, 102, S2-S9. https://doi.org/10.1038/sj.bjc.6605599
|
[29]
|
Allman-Farinelli, M.A. (2011) Obesity and Venous Thrombosis: A Review. Seminars in Thrombosis and Hemostasis, 37, 903-907. https://doi.org/10.1055/s-0031-1297369
|
[30]
|
孙启铭, 张国忠, 韩业兴, 谷建平, 李瑞利, 冯国伟. 静脉血栓形成及引发肺栓塞的机制探讨[C]//中国法医学会,公安部物证鉴定中心. 中国法医学理论与实践创新成果精选——全国第九次法医学术交流会论文集: 2013年卷. 北京: 中国人民公安大学出版社, 2013: 35-37.
|
[31]
|
Watson, S.P. (2009) Platelet Activation by Extracellular Matrix Proteins in Haemostasis and Thrombosis. Current Pharmaceutical Design, 15, 1358-1372. https://doi.org/10.2174/138161209787846702
|
[32]
|
Di Perri, T., Notari, M. and Assogna, G. (1991) Ridogrel, a New Platelet Antiaggregant Molecule with a Double Mechanism of Action. A Pharmacological and Clinical Profile. Re-centi Progressi in Medicina, 82, 533-540.
|
[33]
|
Nakamura, K. and Kawahito, K. (2010) Erythrocyte-Protective Effect of Sarpogrelate Hydrochloride (Anplag®), a Selective 5-HT2 Receptor Antagonist: An in Vitro Study. Journal of Artificial Organs, 13, 178-181.
https://doi.org/10.1007/s10047-010-0515-y
|
[34]
|
Adams, J.W., Ramirez, J., Shi, Y., et al. (2009) APD791, 3-Methoxy-N-(3-(1-Methyl-1H-Pyrazol-5-yl)-4-(2-Morpholinoethoxy)Phenyl)Benzamide, a Novel 5-Hydroxytryptamine 2A Receptor Antagonist: Pharmacological Profile, Pharmacokinetics, Platelet Activity and Vascular Biology. The Journal of Pharmacology and Experimental Therapeutics, 331, 96-103. https://doi.org/10.1124/jpet.109.153189
|
[35]
|
Serebruany, V.L., Fortmann, S.D., Rao, S.V., et al. (2016) Vorapaxar and Diplopia: Possible off-Target PAR-Receptor Mismodulation. Thrombosis and Haemostasis, 115, 905-910. https://doi.org/10.1160/TH15-11-0882
|
[36]
|
Tummala, R. and Rai, M.P. (2022) Glycoprotein IIb/IIIa Inhibitors. In: StatPearls, StatPearls Publishing, Treasure Island.
|
[37]
|
季顺东. 血栓形成机制及抗凝药物的药理特点[J]. 中国计划生育和妇产科, 2021, 13(3): 25-28.
|
[38]
|
Warkentin, T.E., Greinacher, A. and Koster, A. (2008) Bivalirudin. Throm-bosis and Haemostasis, 99, 830-839.
https://doi.org/10.1160/TH07-10-0644
|
[39]
|
McKeage, K. and Plosker, G.L. (2001) Argatroban. Drugs, 61, 515-522.
https://doi.org/10.2165/00003495-200161040-00005
|
[40]
|
Lin, S., Wang, Y., Zhang, L. and Guan, W. (2019) Dabigatran Must Be Used Carefully: Literature Review and Recommendations for Management of Adverse Events. Drug Design, Development and Therapy, 13, 1527-1533.
https://doi.org/10.2147/DDDT.S203112
|
[41]
|
Büller, H.R., Prins, M.H., Lensin, A.W., et al. (2012) Oral Rivarox-aban for the Treatment of Symptomatic Pulmonary Embolism. The New England Journal of Medicine, 366, 1287-1297. https://doi.org/10.1056/NEJMoa1113572
|
[42]
|
Agnelli, G., Buller, H.R., Cohen, A., et al. (2013) Apixaban for Ex-tended Treatment of Venous Thromboembolism. The New England Journal of Medicine, 368, 699-708. https://doi.org/10.1056/NEJMoa1207541
|
[43]
|
(2011) Edoxaban Tosylate. American Journal of Cardiovascular Drugs, 11, 129-135.
https://doi.org/10.2165/11533660-000000000-00000
|
[44]
|
Zhang, Y., Zhang, M., Tan, L., Pan, N. and Zhang, L. (2019) The Clinical Use of Fondaparinux: A Synthetic Heparin Pentasaccharide. In: Zhang, L., Ed., Glycans and Gly-cosaminoglycans as Clinical Biomarkers and Therapeutics—Part B. Progress in Molecular Biology and Translational Science, Vol. 163, Elsevier, Amsterdam, 41-53.
https://doi.org/10.1016/bs.pmbts.2019.02.004
|
[45]
|
Onishi, A., St Ange, K., Dordick, J.S. and Linhardt, R.J. (2016) Heparin and Anticoagulation. Frontiers in Bioscience, 21, 1372-1392. https://doi.org/10.2741/4462
|
[46]
|
Kunamneni, A. and Durvasula, R. (2014) Streptokinase—A Drug for Thrombo-lytic Therapy: A Patent Review. Recent Advances in Cardiovascular Drug Discovery, 9, 106-121. https://doi.org/10.2174/1574890110999150202150017
|
[47]
|
Kadir, R.R.A. and Bayraktutan, U. (2020) Urokinase Plasminogen Activator: A Potential Thrombolytic Agent for Ischaemic Stroke. Cellular and Molecular Neurobiology, 40, 347-355. https://doi.org/10.1007/s10571-019-00737-w
|
[48]
|
Warach, S.J., Dula, A.N. and Milling Jr., T.J. (2020) Tenecteplase Thrombolysis for Acute Ischemic Stroke. Stroke, 51, 3440-3451. https://doi.org/10.1161/STROKEAHA.120.029749
|